Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes

Journal of Clinical Oncology

Volumn 26, Issue 36, 2008, Pages 5943-5949

  Sekeres, Mikkael A ^a   Maciejewski, Jaroslaw P ^a   Giagounidis, Aristotle A N ^a   Wride, Kenton ^a   Knight, Robert ^a   Raza, Azra ^a   List, Alan F ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE;

ADULT; AGED; ARTICLE; CHROMOSOME DELETION 5; CONTROLLED STUDY; CYTOPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; THALIDOMIDE; THROMBOCYTOPENIA;

EID: 58049221263     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.5770     Document Type: Article

References (34)

1. List AF, Vardiman J, Issa JP, et al: Myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 297-317, 2004
2. Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10:1419-1432, 1999
3. Ma X, Does M, Raza A, et al: Myelodysplastic syndromes: Incidence and survival in the United States. Cancer 109:1536-1542, 2007
4. Rollison DE, Hayat M, Smith M, et al: First report of national estimates of the incidence of myelodysplastic syndromes and chronic myeloproliferative disorders from the U.S. SEER Program. Blood 108:77a, 2006 (suppl; abstr 247)
5. Sekeres MA, Kantarjian H, List A, et al: P127 Prospective cross-sectional analysis of cytopenias and transfusion needs of MDS patients in the USA. Leuk Res 31:S108, 2007 (suppl 1)
6. Golshayan AR, Jin T, Maciejewski J, et al: Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 137:125-132, 2007
7. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
8. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440, 2002
9. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
10. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006
11. Cheson BD, Bennett JM, Kantarjian H, et al: Myelodysplastic syndromes standardized response criteria: Further definition. Blood 98:1985, 2001
12. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425, 2006
13. Silverman LR, McKenzie DR, Peterson BL, et al: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-3903, 2006
14. Corral LG, Kaplan G: Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 58:I107-I113, 1999 (suppl 1)
15. Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216, 2001
16. Geitz H, Handt S, Zwingenberger K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213-221, 1996
17. List A, Tate W, Glinsmann-Gibson B: The immunomodulatory thalidomide analog, CC-5013, inhibits tropic response in VEGF in AML cells by abolishing cytokine-induced PI3/Akt activation. Blood 100:139a, 2002 (suppl; abstr 521)
18. Parman T, Wiley MJ, Wells PG: Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585, 1999
19. Buesche G, Dieck S, Giagounidis A, et al: Anti-angiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease. Blood 106:113a, 2005 (suppl; abstr 372)
20. List AF, Dewald GW, Bennett JM, et al: Long-term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome and chromosome deletion 5q. Blood 108:78a, 2006 (suppl; abstr 251)
21. Raza A, Reeves JE, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86-93, 2008
22. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007
23. Raza A, Meyer P, Dutt D, et al: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958-965, 2001
24. Schiller GJ, Slack J, Hainsworth JD, et al: Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 24:2456-2464, 2006
25. Vey N, Bosly A, Guerci A, et al: Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study. J Clin Oncol 24:2465-2471, 2006
26. Ebert BL, Pretz J, Bosco J, et al: Identification of RPS14 as the 5q-syndrome gene by RNA interference screen. Blood 110:8a, 2007 (suppl; abstr 1)
27. Wei S, Rocha K, Williams A, et al: Gene dosage of the cell cycle regulatory phosphatases Cdc25C and PP2A determines sensitivity to lenalidomide in del(5q) MDS. Blood 110:43a, 2007 (suppl; abstr 118)
28. Roboz GJ, Ritchie EK, Allen-Bard S, et al: Arsenic trioxide (ATO) is safe and effective in combination with low-dose Ara-C (LDAC) for the treatment of IPSS-2 myelodysplastic syndrome (MDS) and poor-prognosis acute myeloid leukemia (AML) in elderly patients. Blood 106:786a, 2005 (suppl; abstr 2805)
29. Sekeres MA, Kalaycio ME, Erba HP, et al: P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS. Leuk Res 31:S125, 2007 (suppl 1)
30. Malcovati L, Germing U, Kuendgen A, et al: A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. Blood 106:316a, 2005 (suppl; abstr 788)
31. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
32. O'Keefe CL, Tiu R, Gondek LP, et al: High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. Exp Hematol 35:240-251, 2007
33. Babicka L, Ransdorfova S, Brezinova J, et al: Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH. Leuk Res 31:39-47, 2007
34. Gondek LP, Haddad A, O'Keefe C, et al: SNP karyotyping in myelodysplastic syndromes (MDS) reveals the presence of cryptic karyotypic abnormalities, including uniparental disomy, and has important prognostic implications. Blood 108:265a, 2006 (suppl; abstr 853)